πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

672 results for β€œNan” Clear

  1. low-dose lymphocyte immunotherapy

    Nanjing Zenshine Pharmaceuticals

    Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

    phase 2 other completed

    1 trial

  2. nanoliposomal irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head & Neck Cancer

    phase 2 small molecule completed

    1 trial

  3. nanoparticle albumin-bound paclitaxel/carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. recombinant human Angiostatin protein

    CASI Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  5. recombinant human endostatin

    Peking University Third Hospital

    Melanoma

    phase 2 small molecule active

    1 trial

  6. recombinant human erythropoietin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypoxic-Ischemic Encephalopathy

    phase 2 small molecule completed

    1 trial

  7. recombinant human erythropoietin (rhEpo)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Infant, Premature

    phase 2 small molecule active

    1 trial

  8. recombinant human growth hormone

    Affiliated Hospital of Jiangnan University

    Phelan-McDermid Syndrome

    phase 2 small molecule completed

    1 trial

  9. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  10. toripalimab

    The First People's Hospital of Lianyungang

    Malignant Melanoma

    phase 2 small molecule active

    1 trial

  11. zelicapavir

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule active

    1 trial

  12. 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HPV Infection

    phase 1 mab completed

    1 trial

  13. 18F-FAPIBiotin

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  14. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 small molecule active

    1 trial

  15. 610

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma

    phase 1 small molecule active

    1 trial

  16. 68Ga-JH04

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  17. 68Ga-JH12

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  18. 89ZrΛ—DFOΛ—REGN3504

    Regeneron UK Limited

    Advanced PD-L1 Positive Malignancies

    phase 1 small molecule terminated

    1 trial

  19. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  20. A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies

    Lacuna Pharma Pty Ltd

    Advanced Malignancies

    phase 1 other active

    1 trial

  21. A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product

    Century Therapeutics

    Hematological or solid tumor malignancies or autoimmune diseases

    phase 1 other active

    1 trial

  22. A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD)

    Cullinan Therapeutics

    Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)

    phase 1 other active

    1 trial

  23. A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  24. A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

    Hutchmed Europe B.V.

    - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources